Walter H Moos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1074291/publications.pdf

Version: 2024-02-01

90 papers	4,910 citations	172443 29 h-index	91872 69 g-index
96 all docs	96 docs citations	96 times ranked	4195 citing authors

#	Article	IF	Citations
1	Treatment and prevention of pathological mitochondrial dysfunction in retinal degeneration and in photoreceptor injury. Biochemical Pharmacology, 2022, 203, 115168.	4.4	10
2	Are inâ€person scientific conferences dead or alive?. FASEB BioAdvances, 2021, 3, 420-427.	2.4	12
3	Pathogenic mitochondrial dysfunction and metabolic abnormalities. Biochemical Pharmacology, 2021, 193, 114809.	4.4	21
4	Klotho Pathways, Myelination Disorders, Neurodegenerative Diseases, and Epigenetic Drugs. BioResearch Open Access, 2020, 9, 94-105.	2.6	17
5	Epigenetic treatment of dermatologic disorders. Drug Development Research, 2019, 80, 702-713.	2.9	1
6	Building on Success: A Bright Future for Peptide Therapeutics. Protein and Peptide Letters, 2019, 25, 1044-1050.	0.9	23
7	Peptides 2020: A Clear Therapeutic Vision. Protein and Peptide Letters, 2019, 25, 1042-1043.	0.9	3
8	A New Approach to Treating Neurodegenerative Otologic Disorders. BioResearch Open Access, 2018, 7, 107-115.	2.6	10
9	Gut Microbiota and Salivary Diagnostics: The Mouth Is Salivating to Tell Us Something. BioResearch Open Access, 2017, 6, 123-132.	2.6	45
10	Epigenetic Treatment of Persistent Viral Infections. Drug Development Research, 2017, 78, 24-36.	2.9	17
11	Epigenetic Treatment of Neurodegenerative Ophthalmic Disorders: An Eye Toward the Future. BioResearch Open Access, 2017, 6, 169-181.	2.6	13
12	Chemical development. , 2017, , 459-466.		0
13	FDA path and process. , 2017, , 467-485.		0
14	Graduate and postgraduate education at a crossroads. , 2017, , 103-128.		1
15	Drug discovery. , 2017, , 281-420.		1
16	Drug discovery. , 2017, , 183-279.		1
17	Research and discovery. , 2017, , 421-436.		0
18	Doctoral and professional programs. , 2017, , 141-169.		0

#	Article	IF	Citations
19	Backgrounder. , 2017, , 3-29.		0
20	Masterâ€™s degree programs. , 2017, , 129-139.		3
21	Turning a potent agent into a registered product. , 2017, , 439-447.		0
22	Epigenetic Treatment of Neurodegenerative Disorders: Alzheimer and Parkinson Diseases. Drug Development Research, 2016, 77, 109-123.	2.9	49
23	Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia. Drug Development Research, 2016, 77, 53-72.	2.9	30
24	Microbiota and Neurological Disorders: A Gut Feeling. BioResearch Open Access, 2016, 5, 137-145.	2.6	108
25	Mitochondrial Drugs Come of Age. Drug Development Research, 2015, 76, 57-60.	2.9	9
26	Bioprotective Carnitinoids: Lipoic Acid, Butyrate, and Mitochondriaâ€Targeting to Treat Radiation Injury: Mitochondrial Drugs Come of Age. Drug Development Research, 2015, 76, 167-175.	2.9	13
27	A tribute to David Triggle. Biochemical Pharmacology, 2015, 98, 360-362.	4.4	4
28	Radiation Drugsâ€”Still a Hot Topic. Drug Development Research, 2014, 75, 1-2.	2.9	1
29	Biomarkersâ€”An Essential Tie That Binds the Future of Drugs and Diagnostics. Drug Development Research, 2013, 74, 63-64.	2.9	7
30	A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents. PLoS ONE, 2013, 8, e60579.	2.5	223
31	Radiation Drugs-A Hot Topic. Drug Development Research, 2012, 73, 229-231.	2.9	5
32	Evaluation of the pK_a values and ionization sequence of bumetanide using ¹H and ¹³C NMR and UV spectroscopy. Drug Development Research, 2011, 72, 416-426.	2.9	4
33	Review of the effects of 17Î±â€estradiol in humans: a less feminizing estrogen with neuroprotective potential. Drug Development Research, 2009, 70, 1-21.	2.9	26
34	Nonprofit organizations and pharmaceutical research and development. Drug Development Research, 2009, 70, 461-471.	2.9	9
35	Bright lights, clearly visible in the healthcare R&D tunnel, could burn out for lack of funds. Drug Development Research, 2009, 70, 457-460.	2.9	1
36	Combinatorial chemistry: oh what a decade or two can do. Molecular Diversity, 2009, 13, 241-245.	3.9	36

#	Article	IF	Citations
37	17Î±â€estradiol: a lessâ€feminizing estrogen. Drug Development Research, 2008, 69, 177-184.	2.9	8
38	Nanobiotechnology: it's a small world after all. Drug Development Research, 2006, 67, 1-3.	2.9	18
39	Development of 17Î±-Estradiol as a Neuroprotective Therapeutic Agent: Rationale and Results from a Phase I Clinical Study. Annals of the New York Academy of Sciences, 2005, 1052, 116-135.	3.8	81
40	Estrogens and Neuroprotection: desperate housewives, lost, and survivor. Drug Development Research, 2005, 66, 51-52.	2.9	2
41	Alzheimer's disease, estrogens, and clinical trials: a case study in drug development for complex disorders. Drug Development Research, 2005, 66, 53-77.	2.9	6
42	Ethical Issues in the Biotechnology and Pharmaceutical Industries. Drug Development Research, 2004, 63, 89-92.	2.9	3
43	Efficient Syntheses of Benzothiazepines as Antagonists for the Mitochondrial Sodiumâ^'Calcium Exchanger:Â Potential Therapeutics for Type II Diabetes. Journal of Organic Chemistry, 2003, 68, 92-103.	3.2	48
44	The Biotechnology industry in a period of opportunity and uncertainty. Drug Development Research, 2002, 57, 45-50.	2.9	5
45	Defining the Mandate of Proteomics in the Post-Genomics Era: Workshop Report. Molecular and Cellular Proteomics, 2002, 1, 763-780.	3.8	73
46	Cell death as a life force. Drug Development Research, 2001, 52, 505-507.	2.9	0
47	Pharmacogenomics 2000. , 2000, 49, 1-3.		2
48	Characterization of Novel Antimicrobial Peptoids. Antimicrobial Agents and Chemotherapy, 1999, 43, 1429-1434.	3.2	116
49	Combinatorial discovery process yields antimicrobial peptoids. Bioorganic and Medicinal Chemistry, 1999, 7, 1781-1785.	3.0	61
50	Mitochondria: The biochemical power plants of cells. , 1999, 46, 1-1.		2
51	Introduction to mitochondrial function and genomics. , 1999, 46, 2-13.		10
52	Foreword. , 1998, 61, 5-6.		0
53	Design and Synthesis of m1-Selective Muscarinic Agonists:Â (R)-(â^')-(Z)-1-Azabicyclo[2.2.1]heptan-3-one,O-(3-(3â€²-Methoxyphenyl)-2-propynyl)- oxime Maleate (CI-1017), a Functionally m1-Selective Muscarinic Agonist. Journal of Medicinal Chemistry, 1998, 41, 2524-2536.	6.4	29
54	From genes to drugs: Better, faster, cheaper. , 1997, 41, 111-111.		4

#	Article	IF	Citations
55	Diagnosing the decline of major pharmaceutical research laboratories: A prescription for drug companies. Drug Development Research, 1995, 34, 243-259.	2.9	39
56	Comparison of the proteolytic susceptibilities of homologous L-amino acid, D-amino acid, and N-substituted glycine peptide and peptoid oligomers. Drug Development Research, 1995, 35, 20-32.	2.9	383
57	Molecular diversity comes of age !. Molecular Diversity, 1995, 1, 1-3.	3.9	3
58	Measuring Diversity: Experimental Design of Combinatorial Libraries for Drug Discovery. Journal of Medicinal Chemistry, 1995, 38, 1431-1436.	6.4	375
59	Post-modification of peptoid side chains: [3+2] cycloaddition of nitrile oxides with alkenes and alkynes on the solid-phase. Tetrahedron Letters, 1994, 35, 5825-5828.	1.4	65
60	Proteolytic studies of homologous peptide and N-substituted glycine peptoid oligomers. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 2657-2662.	2.2	289
61	Recent advances in the generation of chemical diversity libraries. Drug Development Research, 1994, 33, 174-188.	2.9	58
62	Discovery of Nanomolar Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted)glycine Peptoid Library. Journal of Medicinal Chemistry, 1994, 37, 2678-2685.	6.4	378
63	Using Peptoid Libraries [Oligo N-Substituted Glycines] for Drug Discovery. Techniques in Protein Chemistry, 1994, 5, 533-539.	0.3	13
64	Pharmaceutical applications of biotechnology: Promise and reality. Editorial overview. Current Opinion in Biotechnology, 1993, 4, 711-713.	6.6	6
65	The generation of molecular diversity. Bioorganic and Medicinal Chemistry Letters, 1993, 3, 387-396.	2.2	116
66	Chapter 33. Recent Advances in the Generation of Molecular Diversity. Annual Reports in Medicinal Chemistry, 1993, , 315-324.	0.9	76
67	Efficient method for the preparation of peptoids [oligo(N-substituted glycines)] by submonomer solid-phase synthesis. Journal of the American Chemical Society, 1992, 114, 10646-10647.	13.7	1,139
68	Cholinomimetics and Alzheimer's disease. Bioorganic and Medicinal Chemistry Letters, 1992, 2, 777-780.	2.2	21
69	Cholinergic agents: aldehyde, ketone, and oxime analogues of the muscarinic agonist UH5. Bioorganic and Medicinal Chemistry Letters, 1992, 2, 803-808.	2.2	22
70	Acetylcholine releasing agents as cognition activators. Chemistry and pharmacology of a series of ureas. Bioorganic and Medicinal Chemistry Letters, 1992, 2, 855-860.	2.2	1
71	Cholinergic Agents: Effect of Methyl Substitution in a Series of Arecoline Derivatives on Binding to Muscarinic Acetylcholine Receptors. Journal of Pharmaceutical Sciences, 1992, 81, 1015-1019.	3.3	12
72	A silica gel plate-based qualitative assay for acetylcholinesterase activity: A mass method to screen for potential inhibitors. Analytical Biochemistry, 1991, 196, 439-442.	2.4	28

#	Article	IF	Citations
73	Cholinergic agents: Deficits in rat hippocampal choline acetyltransferase activity and spatial working memory induced by intracerebroventricular administration of stoichiometrically prepared 1-ethyl-1-(2-hydroxyethyl) aziridinium ion (AF64A). Drug Development Research, 1991, 23, 253-260.	2.9	0
74	Conformation of three tetrahydropyridinyl oxime cognition activators. Journal of Crystallographic and Spectroscopic Research, 1991, 21, 419-429.	0.2	2
75	Novel Muscarinic Agonists for the Treatment of Alzheimerâ€™s Disease. , 1991, , 347-353.		4
76	Benzo-fused bicyclic imides. Journal of Organic Chemistry, 1990, 55, 560-564.	3.2	30
77	The Muscarinic Receptors. The Receptors.Joan Heller Brown. Quarterly Review of Biology, 1990, 65, 381-381.	0.1	0
78	Evaluation in rats of the somnogenic, pyrogenic, and central nervous system depressant effects of muramyl dipeptide. Psychopharmacology, 1989, 99, 103-108.	3.1	42
79	A SIMPLIFIED PROCEDURE FOR PREPARING THE CHOLINERGIC NEUROTOXIN 1-ETHYL-1-(2-EYDROXYETHYL)AZIRIDINIUM ION (AF64A). Organic Preparations and Procedures International, 1989, 21, 315-319.	1.3	5
80	Adenosine Receptor Agonists. X-Ray Crystal Structure of Neca 1-(6-Amino-9<u>H</u>-Purin-9-Yl)-1-Deoxy-N-Ethyl-Î²-D-Ribofuranuronamide. Nucleosides & Nucleotides, 1989, 8, 449-461.	0.5	7
81	Cognition activators. Medicinal Research Reviews, 1988, 8, 353-391.	10.5	100
82	Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity. Journal of Medicinal Chemistry, 1987, 30, 1963-1972.	6.4	89
83	N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity. Journal of Medicinal Chemistry, 1987, 30, 1709-1711.	6.4	54
84	Drug development for senile cognitive decline. Journal of Medicinal Chemistry, 1986, 29, 1125-1130.	6.4	45
85	Ribose-modified adenosine analogs as adenosine receptor agonists. Journal of Medicinal Chemistry, 1986, 29, 346-353.	6.4	53
86	Chapter 4. Cognitive Disorders. Annual Reports in Medicinal Chemistry, 1986, , 31-40.	0.9	1
87	The reaction of pyridazinones with nucleophiles. An unusual reaction with cyanide. Journal of Heterocyclic Chemistry, 1986, 23, 1515-1517.	2.6	7
88	Studies on the Preparation, Isolation, and Reactions of Adenosine Schiff Bases. Nucleosides & Nucleotides, 1986, 5, 201-212.	0.5	0
89	N6-Cycloalkyladenosines. Potent, A1-selective adenosine agonists. Journal of Medicinal Chemistry, 1985, 28, 1383-1384.	6.4	104
90	Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure. Journal of Medicinal Chemistry, 1984, 27, 1099-1101.	6.4	159